Erratum: Saporin as a novel suicide gene in anticancer gene therapy (Cancer Gene Theraphy (2007) 14, (165-173) DOI: 10.1038/sj.cgt.7700998);Saporin as a novel suicide gene in anticancer gene therapy

Cancer Gene Therapy

Volumn 14, Issue 2, 2007, Pages 165-173

  Zarovni, N ^a   Vago, R ^a,b   Solda T ^a,c   Monaco, L ^a,d   Fabbrini, M S ^a,b,e  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b CNR   (Italy)

^c Istituto per la Ricerca Biomedica   (Switzerland)

^d Telethon Onlus   (Italy)

^e CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

Anticancer gene therapy; Melanoma; Non viral gene delivery; Plant ribosome inactivating protein; Suicide gene expression

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; GLYCOSIDASE; LIPOFECTAMINE; LUCIFERASE; MUTANT PROTEIN; POLYETHYLENEIMINE DERIVATIVE; RIBOSOME INACTIVATING PROTEIN; SAPORIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER THERAPY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG TARGETING; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC CODE; GENETIC TRANSFECTION; MELANOMA; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN SYNTHESIS INHIBITION; REPEAT PROCEDURE; REPORTER GENE; SIMIAN VIRUS 40; SUICIDE GENE; SUICIDE GENE THERAPY;

CYTOMEGALOVIRUS; MUS; SIMIAN VIRUS 40;

EID: 33846238540     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701046     Document Type: Erratum

References (51)

1. Ostrand-Rosenberg S, Baskar S, Patterson N, Clements VK. Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells. Tissue Antigens 1996; 47: 414-421.
2. Finn OJ. Cancer vaccines: between the idea and the reality. Nat RevImmunol 2003; 3: 630-641.
3. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005; 5: 436-446.
4. Lin P, Buxton JA, Acheson A, Radziejewski C, Maisonpierre PC, Yancopoulos GD et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci USA 1998; 95: 8829-8834.
5. Dachs GU, Tupper J, Tozer GM. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 2005; 16: 349-359.
6. Anderson DG, Peng W, Akinc A, Hossain N, Kohn A, Padera R et al. A polymer library approach to suicide gene therapy for cancer. Proc Natl Acad Sci USA 2004; 101: 16028-16033.
7. Zheng JY, Chen D, Chan J, Yu D, Ko E, Pang S. Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A. Cancer Gene Ther 2003; 10: 764-770.
8. Yerushalmi N, Brinkmann U, Brinkmann E, Pai L, Pastan I. Attenuating the growth of tumors by intratumoral administration of DNA encoding Pseudomonas exotoxin via cationic liposomes. Cancer Gene Ther 2000; 7: 91-96.
9. Martin V, Cortes ML, de Felipe P, Farsetti A, Calcaterra NB, Izquierdo M. Cancer gene therapy by thyroid hormonemediated expression of toxin genes. Cancer Res 2000; 60: 3218-3224.
10. Rodriguez R, Lim HY, Bartkowski LM, Simons JW. Identification of diphtheria toxin via screening as a potent cell cycle and p53-independent cytotoxin for human prostate cancer therapeutics. Prostate 1998; 34: 259-269.
11. Fabbrini MS, Flavell DJ, Ippoliti R. Plant protein toxins: structure, function and biotechnological applications. In: Ascenzi P, Polticelli Fa, Visca P (eds) Bacterial, Plant & Animal Toxins. Research Signpost: Kerala, India, 2003, pp. 69-99.
12. Barbieri L, Battelli MG, Stirpe F. Ribosome-inactivating proteins from plants. Biochim Biophys Acta 1993; 1154: 237-282.
13. Roncuzzi L, Gasperi-Campani A. DNA-nuclease activity of the single-chain ribosome-inactivating proteins Dianthin 30, Saporin 6 and Gelonin. FEBS Lett 1996; 392: 16-20.
14. Bagga S, Seth D, Batra JK. The cytotoxic activity of ribosome- inactivating protein saporin-6 is attributed to its rRNA N-glycosidase and internucleosomal DNA fragmentation activities. J Biol Chem 2003; 278: 4813-4820.
15. Cavallaro U, Nykjaer A, Nielsen M, Soria MR. Alpha 2-macroglobulin receptor mediates binding and cytotoxicity of plant ribosome-inactivating proteins. Eur J Biochem 1995; 232: 165-171.
16. Fabbrini MS, Rappocciolo E, Carpani D, Solinas M, Valsasina B, Breme U et al. Characterization of a saporin isoform with lower ribosome-inhibiting activity. Biochem J 1997; 322: 719-727.
17. Lappi DA, Ying W, Barthelemy I, Martineau D, Prieto I, Benatti L et al. Expression and activities of a recombinant basic fibroblast growth factor-saporin fusion protein. J Biol Chem 1994; 269: 12552-12558.
18. Falini B, Bolognesi A, Flenghi L, Tazzari PL, Broe MK, Stein H et al. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 1992; 339: 1195-1196.
19. Cavallaro U, del Vecchio A, Lappi DA, Soria MR. A conjugate between human urokinase and saporin, a type-1 ribosome-inactivating protein, is selectively cytotoxic to urokinase receptor-expressing cells. J Biol Chem 1993; 268: 23186-23190.
20. Ying W, Martineau D, Beitz J, Lappi DA, Baird A. Anti-B16-F10 melanoma activity of a basic fibroblast growth factor-saporin mitotoxin. Cancer 1994; 74: 848-853.
21. Flavell DJ, Noss A, Pulford KA, Ling N, Flavell SU. Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice. Cancer Res 1997; 57: 4824-4829.
22. Prieto I, Lappi DA, Ong M, Matsunami R, Benatti L, Villares V et al. Expression and characterization of a basic fibroblast growth factor-saporin fusion protein in Escherichia coli. Ann N Y Acad Sci 1991; 638: 434-437.
23. Fabbrini MS, Carpani D, Bello-Rivero I, Soria MR. The amino-terminal fragment of human urokinase directs a recombinant chimeric toxin to target cells: internalization is toxin mediated. FASEB J 1997; 11: 1169-1176.
24. Heisler I, Keller J, Tauber R, Sutherland M, Fuchs H. A cleavable adapter to reduce nonspecific cytotoxicity of recombinant immunotoxins. Int J Cancer 2003; 103: 277-282.
25. Tcherniuk SO, Chroboczek J, Balakirev MY. Construction of tumor-specific toxins using ubiquitin fusion technique. Mol Ther 2005; 11: 196-204.
26. Fabbrini MS, Carpani D, Soria MR, Ceriotti A. Cytosolic immunization allows the expression of preATF-saporin chimeric toxin in eukaryotic cells. FASEB J 2000; 1: 391-398.
27. Zhang S, Xu Y, Wang B, Qiao W, Liu D, Li Z. Cationic compounds used in lipoplexes and polyplexes for gene delivery. J Control Release 2004; 100: 165-180.
28. Goergen JL, Monaco L. Generation of high-recombinant-protein-producing Chinese hamster ovary (CHO) cells. Methods Mol Biol 2004; 267: 477-483.
29. Monaco L, Tagliabue R, Soria MR, Uhlen M. An in vitro amplification approach for the expression of recombinant proteins in mammalian cells. Biotechnol Appl Biochem 1994; 20: 157-171.
30. Demeneix B, Behr JP. Polyethylenimine (PEI). Adv Genet 2005; 53: 215-230.
31. Vago R, Marsden CJ, Lord JM, Ippoliti R, Flavell DJ, Flavell SU et al. Saporin and ricin A chain follow different intracellular routes to enter the cytosol of intoxicated cells. FEBS J 2005; 272: 4983-4995.
32. Wales R, Roberts LM, Lord JM. Addition of an endoplasmic reticulum retrieval sequence to ricin A chain significantly increases its cytotoxicity to mammalian cells. J Biol Chem 1993; 268: 23986-23990.
33. Majoul IV, Bastiaens PI, Soling HD. Transport of an external Lys-Asp-Glu-Leu (KDEL) protein from the plasma membrane to the endoplasmic reticulum: studies with cholera toxin in Vero cells. J Cell Biol 1996; 133: 777-789.
34. Jackson ME, Simpson JC, Girod A, Pepperkok R, Roberts LM, Lord JM. The KDEL retrieval system is exploited by Pseudomonas exotoxin A, but not by Shiga-like toxin-1, during retrograde transport from the Golgi complex to the endoplasmic reticulum. J Cell Sci 1999; 112: 467-475.
35. Dass CR. Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection. J Mol Med 2004; 82: 579-591.
36. Frankel A, Kreitman R, Sausville E. Targeted toxins. Clin Cancer Res 2000; 6: 326-334.
37. Johannes L, Decaudin D. Protein toxins: intracellular trafficking for targeted therapy. Gene Ther 2005; 12: 1360-1368.
38. Pastan II, Kreitman RJ. Immunotoxins for targeted cancer therapy. AdvDrug DelivRev 1998; 31: 53-88.
39. Davol P, Beitz JG, Frackelton Jr AR. Autocrine downregulation of basic fibroblast growth factor receptors causes mitotoxin resistance in a human melanoma cell line. J Invest Dermatol 1995; 104: 916-921.
40. Hoganson DK, Chandler LA, Fleurbaaij GA, Ying W, Black ME, Doukas J et al. Targeted delivery of DNA encoding cytotoxic proteins through high-affinity fibroblast growth factor receptors. Hum Gene Ther 1998; 9: 2565-2575.
41. Bergamaschi G, Perfetti V, Tonon L, Novella A, Lucotti C, Danova M et al. Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis. Br J Haematol 1996; 93: 789-794.
42. Bolognesi A, Tazzari PL, Olivieri F, Polito L, Falini B, Stirpe F. Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins. Int J Cancer 1996; 68: 349-355.
43. Vitetta ES. Immunotoxins and vascular leak syndrome. Cancer J 2000; 6(Suppl 3): S218-S224.
44. Zarovni N, Monaco L, Corti A. Inhibition of tumor growth by intramuscular injection of cDNA encoding tumor necrosis factor a coupled to NGR and RGD tumor-homing peptides. Human Gene Ther 2004; 15: 373-382.
45. Sadeghi H, Hitt MM. Transcriptionally targeted adenovirus vectors. Curr Gene Ther 2005; 5: 411-427.
46. Gommans WM, van Eert SJ, McLaughlin PM, Harmsen MC, Yamamoto M, Curiel DT et al. The carcinoma-specific epithelial glycoprotein-2 promoter controls efficient and selective gene expression in an adenoviral context. Cancer Gene Ther 2006; 13: 150-158.
47. Wirth T, Kuhnel F, Kubicka S. Telomerase-dependent gene therapy. Curr Mol Med 2005; 5: 243-251.
48. Sato M, Johnson M, Zhang L, Gambhir SS, Carey M, Wu L. Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer. Clin Cancer Res 2005; 11: 3743-3749.
49. Lipinski KS, Djeha HA, Gawn J, Cliffe S, Maitland NJ, Palmer DH et al. Optimization of a synthetic beta-catenin-dependent promoter for tumor-specific cancer gene therapy. Mol Ther 2004; 10: 150-161.
50. Zabala M, Wang L, Hernandez-Alcoceba R, Hillen W, Qian C, Prieto J et al. Optimization of the Tet-on system to regulate interleukin 12 expression in the liver for the treatment of hepatic tumors. Cancer Res 2004; 64: 2799-2804.
51. Ndoye A, Bouali S, Dolivet G, Leroux A, Erbacher P, Behr JP et al. Sustained gene transfer and enhanced cell death following glucosylated-PEI- mediated p53 gene transfer with photochemical internalisation in p53-mutated head and neck carcinoma cells. Int J Oncol 2004; 25: 1575-1581.